| 喻 婷,胡德胜,楚 思,刘星星,范 恒.复方苦参汤联合美沙拉嗪对溃疡性结肠炎治疗效果及炎性因子水平的影响[J].现代生物医学进展英文版,2021,(1):50-53. |
| 复方苦参汤联合美沙拉嗪对溃疡性结肠炎治疗效果及炎性因子水平的影响 |
| Effect of Compound Sophorae Decoction Combined with Mesalazine on the Treatment of Ulcerative Colitis and the Level of Inflammatory Factors |
| Received:March 30, 2020 Revised:April 24, 2020 |
| DOI：10.13241/j.cnki.pmb.2021.01.009 |
| 中文关键词: 复方苦参汤 美沙拉嗪 溃疡性结肠炎 炎性因子 黏膜病变 |
| 英文关键词: Compound sophorae decoction Mesalazine Ulcerative colitis Inflammatory factors Mucosal lesions |
| 基金项目:国家自然科学基金项目（81774093） |
|
| Hits: 1021 |
| Download times: 1029 |
| 中文摘要: |
| 摘要 目的：探讨复方苦参汤联合美沙拉嗪对溃疡性结肠炎治疗效果及炎性因子水平的影响。方法：以我院2017年1月至2019年12月中西医结合科和消化内科收治的206例溃疡性结肠炎患者为研究对象，根据随机抽样法将受试者分为对照组和研究组，每组各103例，对照组接受美沙拉嗪治疗，研究组在对照组的基础上口服复方苦参汤治疗，比较两组的治疗总有效率，治疗前后黏膜病变、疾病活动指数与各炎性因子水平变化以及用药安全性。结果：研究组治疗总有效率较对照组高（P＜0.05）；治疗后两组肠镜下黏膜病变与疾病活动指数较治疗前均明显改善，且研究组显著优于对照组(P<0.05)；治疗后两组白细胞介素（interleukine，IL）-6、IL-8、肿瘤坏死因子(tumor necrosis factor, TNF)-α、C反应蛋白(C-reactive protein，CRP)及降钙素原(procallcitonin，PCT)等炎性因子水平较治疗前均显著下降，且研究组低于对照组（P＜0.05）；两组药物所致不良反应发生率比较无统计学差异(P>0.05)。结论：复方苦参汤联合美沙拉嗪可有效缓解临床症状，改善肠道黏膜病变，降低肠道炎性反应，控制病情进展，疗效安全显著，对促进溃疡性结肠炎患者病情康复具有积极意义。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of compound sophorae decoction combined with mesalazine on the treatment of ulcerative colitis and the level of inflammatory factors. Methods: 206 patients with ulcerative colitis were treated in the department of integrated traditional Chinese and western medicine and the department of gastroenterology in our hospital from January 2017 to December 2019, According to the method of random sampling, the subjects were divided into control group and study group, each with 103 cases, the control group was treated with mesalazine, and the study group was treated with compound sophorae decoction orally on the basis of the control group. The total effective rate of treatment, changes in mucosal lesions, disease activity index and inflammatory factors before and after treatment, as well as drug safety were compared between the two groups. Results: The total effective rate of the study group was higher than that of the control group (P<0.05). After treatment, mucosal lesions and disease activity index under colonoscopy were significantly improved in the two groups compared with before treatment, and the study group was significantly better than the control group (P<0.05). After treatment, the levels of IL-6, IL-8, TNF-α, CRP, PCT and other inflammatory factors in the two groups decreased significantly compared with those before treatment, and the levels in the study group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups (P>0.05). Conclusion: Compound sophorae decoction combined with mesalazine can effectively relieve clinical symptoms, improve intestinal mucosal lesions, reduce intestinal inflammatory reaction, control the progress of the disease, the curative effect is safe and significant, and has positive significance for promoting the rehabilitation of patients with ulcerative colitis. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
